Mira Pharmaceuticals (MIRA) Cash from Financing Activities (2022 - 2025)

Mira Pharmaceuticals (MIRA) has 4 years of Cash from Financing Activities data on file, last reported at $4.8 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 881.03% year-over-year to $4.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.2 million (up 115.66% YoY) and the FY2025 annual result came in at $8.2 million, up 115.66% from the prior year.
• Cash from Financing Activities grew to $4.8 million in Q4 2025 per MIRA's latest filing, from $3.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $7.6 million in Q3 2023, with the low at -$230749.0 in Q4 2023.
• Average Cash from Financing Activities over 4 years is $1.6 million, with a median of $680354.5 recorded in 2022.
• The widest YoY moves for Cash from Financing Activities: up 1024.27% in 2023, down 120.26% in 2023.
• Mira Pharmaceuticals' Cash from Financing Activities stood at $1.1 million in 2022, then tumbled by 120.26% to -$230749.0 in 2023, then jumped by 313.83% to $493401.0 in 2024, then soared by 881.03% to $4.8 million in 2025.
• Business Quant data shows MIRA's Cash from Financing Activities at $4.8 million in Q4 2025, $3.0 million in Q3 2025, and $323841.0 in Q2 2025.